gp-2250
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 14, 2019 (NCT03854110)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- NUAK family SNF1-like kinase 2ACTIVATOR
NUAK2 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03854110 | Phase 1/Phase 2 (Phase 2) | Jan 14, 2019 | Geistlich Pharma AG, Harvard University, Translational Drug Development |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Geistlich Pharma AG | For profit | 1 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Translational Drug Development | For profit | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1